Peak Bio, Inc.

Peak Bio, Inc. (Nasdaq: PKBO) is a clinical-stage biopharmaceutical company focused on oncology, formed through the de-SPAC merger of Ignyte Acquisition Corp, which completed its SPAC IPO in 2021. The August 2022 10-Q filing, bearing accession number 0001193125-22-221339, reflects the company's status as a newly public combined entity in the post-merger integration phase. Peak Bio's pipeline centers on antibody-drug conjugate technology targeting solid tumors, placing it squarely within the high-growth oncology segment that attracted significant SPAC activity during that cycle. The company's public debut via the blank-check vehicle brought South Korean drug development assets into U.S. capital markets. Sign up on SpacDesk for full filing history, deal timelines, and sponsor data on PKBO and hundreds of other SPAC transactions.